PEPTIDE CORTEXThe library
← The library

TB-500

Thymosin beta-4 fragment, researchHealing/Recovery
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeHealing / Recovery
MechanismRelated to thymosin beta-4 pathways; tissue repair signaling (experimental)
EffectsRelated to thymosin beta-4 pathways; tissue repair signaling (experimental)
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published1 sourced
Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
FrequencyTwice weekly while loading, once weekly in maintenance
StartingLoading about 2-2.5 mg SC twice weekly, weeks 1-6
EscalationNo escalation; loading then step-down to maintenance
TargetMaintenance about 2-2.5 mg SC once weekly, weeks 7-12 or longer
Cycle8-12 weeks total, then 4-8 weeks off
WhereSubQ; described as systemic — no local placement convention stated.

Not validated by a human trial of the TB-500 fragment; human evidence exists only for full-length thymosin beta-4. Vendors use "TB-500" for both.

Batches on file2
10 mgJA-63075 · 2025-0499.88%
70 mgblend · JA-70756 · 2025-07no purity figure
Read with10
Cautions & interactions

Not FDA-approved; unknown risks; avoid self-administration

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.